nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—VEGFA—psoriasis	0.599	1	CbGaD
Minocycline—SLC22A11—Methotrexate—psoriasis	0.0249	0.27	CbGbCtD
Minocycline—SLC22A7—Methotrexate—psoriasis	0.0237	0.257	CbGbCtD
Minocycline—SLC22A6—Cyclosporine—psoriasis	0.019	0.207	CbGbCtD
Minocycline—IL1B—synovial fluid—psoriasis	0.0159	0.124	CbGeAlD
Minocycline—SLC22A8—Methotrexate—psoriasis	0.0145	0.157	CbGbCtD
Minocycline—MMP9—synovial fluid—psoriasis	0.0132	0.103	CbGeAlD
Minocycline—IL1B—dermis—psoriasis	0.0119	0.0927	CbGeAlD
Minocycline—IL1B—skeletal joint—psoriasis	0.0103	0.08	CbGeAlD
Minocycline—SLC22A6—Methotrexate—psoriasis	0.0101	0.109	CbGbCtD
Minocycline—MMP9—dermis—psoriasis	0.00991	0.0773	CbGeAlD
Minocycline—MMP9—skeletal joint—psoriasis	0.00856	0.0667	CbGeAlD
Minocycline—IL1B—vertebral column—psoriasis	0.00816	0.0636	CbGeAlD
Minocycline—IL1B—synovial membrane of synovial joint—psoriasis	0.0078	0.0608	CbGeAlD
Minocycline—CASP3—skin epidermis—psoriasis	0.00626	0.0488	CbGeAlD
Minocycline—IL1B—skin epidermis—psoriasis	0.005	0.039	CbGeAlD
Minocycline—CASP3—endothelium—psoriasis	0.00454	0.0354	CbGeAlD
Minocycline—MMP9—skin epidermis—psoriasis	0.00417	0.0325	CbGeAlD
Minocycline—IL1B—endothelium—psoriasis	0.00363	0.0283	CbGeAlD
Minocycline—MMP9—endothelium—psoriasis	0.00303	0.0236	CbGeAlD
Minocycline—CASP1—skin of body—psoriasis	0.00235	0.0183	CbGeAlD
Minocycline—CYCS—skin of body—psoriasis	0.00227	0.0177	CbGeAlD
Minocycline—CASP3—skin of body—psoriasis	0.00194	0.0151	CbGeAlD
Minocycline—CASP1—tendon—psoriasis	0.00179	0.014	CbGeAlD
Minocycline—IL1B—skin of body—psoriasis	0.00155	0.0121	CbGeAlD
Minocycline—CASP3—tendon—psoriasis	0.00148	0.0115	CbGeAlD
Minocycline—MMP9—skin of body—psoriasis	0.00129	0.0101	CbGeAlD
Minocycline—IL1B—tendon—psoriasis	0.00118	0.0092	CbGeAlD
Minocycline—VEGFA—tendon—psoriasis	0.00116	0.00905	CbGeAlD
Minocycline—MMP9—tendon—psoriasis	0.000983	0.00766	CbGeAlD
Minocycline—CYCS—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.000748	0.111	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Clobetasol propionate—psoriasis	0.000412	0.0613	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Fluocinonide—psoriasis	0.00033	0.0491	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Fluocinolone Acetonide—psoriasis	0.000321	0.0477	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Clobetasol propionate—psoriasis	0.000256	0.038	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Beclomethasone—psoriasis	0.000205	0.0304	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Fluocinonide—psoriasis	0.000205	0.0304	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Fluocinolone Acetonide—psoriasis	0.000199	0.0296	CbGdCrCtD
Minocycline—IL1B—Budesonide—Clobetasol propionate—psoriasis	0.000171	0.0254	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Hydrocortisone—psoriasis	0.000162	0.0241	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Dexamethasone—psoriasis	0.000151	0.0224	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Betamethasone—psoriasis	0.000151	0.0224	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Triamcinolone—psoriasis	0.000147	0.0219	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Prednisone—psoriasis	0.00014	0.0207	CbGdCrCtD
Minocycline—IL1B—Budesonide—Beclomethasone—psoriasis	0.000137	0.0203	CbGdCrCtD
Minocycline—IL1B—Budesonide—Fluocinonide—psoriasis	0.000137	0.0203	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Prednisolone—psoriasis	0.000136	0.0202	CbGdCrCtD
Minocycline—IL1B—Budesonide—Fluocinolone Acetonide—psoriasis	0.000133	0.0197	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Clobetasol propionate—psoriasis	0.000104	0.0155	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Clobetasol propionate—psoriasis	0.000104	0.0155	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Hydrocortisone—psoriasis	0.0001	0.0149	CbGdCrCtD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	9.81e-05	0.000564	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—TNF—psoriasis	9.77e-05	0.000562	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—HLA-B—psoriasis	9.77e-05	0.000561	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—TYK2—psoriasis	9.75e-05	0.00056	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—JUN—psoriasis	9.67e-05	0.000556	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-C—psoriasis	9.62e-05	0.000553	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—TNF—psoriasis	9.61e-05	0.000552	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CARM1—psoriasis	9.6e-05	0.000551	CbGpPWpGaD
Minocycline—VEGFA—Differentiation Pathway—IL6—psoriasis	9.6e-05	0.000551	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—CXCL8—psoriasis	9.58e-05	0.000551	CbGpPWpGaD
Minocycline—CYCS—Apoptosis—TNF—psoriasis	9.57e-05	0.00055	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—TYK2—psoriasis	9.55e-05	0.000548	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—NFKBIA—psoriasis	9.53e-05	0.000548	CbGpPWpGaD
Minocycline—CASP1—Immune System—TNFAIP3—psoriasis	9.51e-05	0.000546	CbGpPWpGaD
Minocycline—CASP3—BDNF signaling pathway—STAT3—psoriasis	9.47e-05	0.000544	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—IL6—psoriasis	9.46e-05	0.000544	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.45e-05	0.000543	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.43e-05	0.000542	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	9.34e-05	0.000537	CbGpPWpGaD
Minocycline—MMP9—EPH-Ephrin signaling—VEGFA—psoriasis	9.34e-05	0.000536	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Betamethasone—psoriasis	9.33e-05	0.0139	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Dexamethasone—psoriasis	9.33e-05	0.0139	CbGdCrCtD
Minocycline—CASP3—MAPK Signaling Pathway—NFKB1—psoriasis	9.31e-05	0.000535	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—JUN—psoriasis	9.29e-05	0.000534	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—TNF—psoriasis	9.28e-05	0.000533	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—TP53—psoriasis	9.25e-05	0.000531	CbGpPWpGaD
Minocycline—IL1B—Immune System—DDX58—psoriasis	9.22e-05	0.00053	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	9.22e-05	0.00053	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—VEGFA—psoriasis	9.21e-05	0.000529	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Triamcinolone—psoriasis	9.12e-05	0.0135	CbGdCrCtD
Minocycline—CASP3—Signaling Pathways—TAGAP—psoriasis	9.03e-05	0.000519	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	8.99e-05	0.000517	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—CXCL8—psoriasis	8.98e-05	0.000516	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—VEGFA—psoriasis	8.97e-05	0.000515	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—NFKB1—psoriasis	8.96e-05	0.000515	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—NFKB1—psoriasis	8.94e-05	0.000514	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—TP53—psoriasis	8.93e-05	0.000513	CbGpPWpGaD
Minocycline—IL1B—Selenium Micronutrient Network—IL6—psoriasis	8.88e-05	0.00051	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—ITGAL—psoriasis	8.87e-05	0.00051	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—ICAM1—psoriasis	8.85e-05	0.000508	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—JUN—psoriasis	8.76e-05	0.000503	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.73e-05	0.000502	CbGpPWpGaD
Minocycline—IL1B—TCR Signaling Pathway—IL6—psoriasis	8.72e-05	0.000501	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TNF—psoriasis	8.7e-05	0.0005	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisone—psoriasis	8.65e-05	0.0129	CbGdCrCtD
Minocycline—CASP1—Innate Immune System—CRP—psoriasis	8.64e-05	0.000496	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CYP2S1—psoriasis	8.6e-05	0.000494	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—TP53—psoriasis	8.47e-05	0.000487	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CAT—psoriasis	8.46e-05	0.000486	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisolone—psoriasis	8.44e-05	0.0125	CbGdCrCtD
Minocycline—CYCS—Apoptosis—TP53—psoriasis	8.44e-05	0.000485	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—NFKB1—psoriasis	8.43e-05	0.000484	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—TP53—psoriasis	8.42e-05	0.000484	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.4e-05	0.000483	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Beclomethasone—psoriasis	8.36e-05	0.0124	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Fluocinonide—psoriasis	8.36e-05	0.0124	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Beclomethasone—psoriasis	8.36e-05	0.0124	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Fluocinonide—psoriasis	8.36e-05	0.0124	CbGdCrCtD
Minocycline—CYCS—Cellular responses to stress—JUN—psoriasis	8.35e-05	0.00048	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CARM1—psoriasis	8.33e-05	0.000479	CbGpPWpGaD
Minocycline—VEGFA—SHP2 signaling—IL6—psoriasis	8.25e-05	0.000474	CbGpPWpGaD
Minocycline—VEGFA—Oncostatin M Signaling Pathway—TP53—psoriasis	8.23e-05	0.000473	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—IL6—psoriasis	8.18e-05	0.00047	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Fluocinolone Acetonide—psoriasis	8.12e-05	0.0121	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Fluocinolone Acetonide—psoriasis	8.12e-05	0.0121	CbGdCrCtD
Minocycline—IL1B—SIDS Susceptibility Pathways—VEGFA—psoriasis	8.12e-05	0.000466	CbGpPWpGaD
Minocycline—MMP9—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	8.11e-05	0.000466	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—STAT3—psoriasis	8.05e-05	0.000463	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—NFKB1—psoriasis	8.04e-05	0.000462	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-E—psoriasis	7.99e-05	0.000459	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—TNF—psoriasis	7.98e-05	0.000459	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	7.94e-05	0.000456	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—CP—psoriasis	7.91e-05	0.000455	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—IL6—psoriasis	7.89e-05	0.000453	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—NFKBIA—psoriasis	7.88e-05	0.000453	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—TYK2—psoriasis	7.81e-05	0.000449	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL6—psoriasis	7.76e-05	0.000446	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—psoriasis	7.73e-05	0.000444	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—IL6—psoriasis	7.71e-05	0.000443	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—TNF—psoriasis	7.69e-05	0.000442	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TP53—psoriasis	7.67e-05	0.000441	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	7.63e-05	0.000438	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.63e-05	0.000438	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—CARM1—psoriasis	7.55e-05	0.000434	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL6—psoriasis	7.53e-05	0.000433	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—IL6—psoriasis	7.49e-05	0.00043	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—VEGFA—psoriasis	7.3e-05	0.000419	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TNF—psoriasis	7.24e-05	0.000416	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HCAR2—psoriasis	7.23e-05	0.000415	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—STAT3—psoriasis	7.22e-05	0.000415	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—TYK2—psoriasis	7.19e-05	0.000413	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	7.18e-05	0.000412	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—ICAM1—psoriasis	7.11e-05	0.000409	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—IL6—psoriasis	7.02e-05	0.000403	CbGpPWpGaD
Minocycline—IL1B—Immune System—ITGAL—psoriasis	6.99e-05	0.000401	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—TNF—psoriasis	6.96e-05	0.0004	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—TP53—psoriasis	6.96e-05	0.0004	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	6.85e-05	0.000393	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CARM1—psoriasis	6.82e-05	0.000392	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TP53—psoriasis	6.81e-05	0.000391	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IFNG—psoriasis	6.73e-05	0.000387	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Hydrocortisone—psoriasis	6.71e-05	0.00997	CbGdCrCtD
Minocycline—MMP9—Signaling by SCF-KIT—STAT3—psoriasis	6.68e-05	0.000384	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TNF—psoriasis	6.67e-05	0.000383	CbGpPWpGaD
Minocycline—CASP1—Immune System—SOCS1—psoriasis	6.67e-05	0.000383	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.65e-05	0.000382	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TNF—psoriasis	6.56e-05	0.000377	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.54e-05	0.000376	CbGpPWpGaD
Minocycline—IL1B—Immune System—REL—psoriasis	6.54e-05	0.000376	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—TYK2—psoriasis	6.45e-05	0.000371	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TP53—psoriasis	6.39e-05	0.000367	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—JUN—psoriasis	6.35e-05	0.000365	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFIH1—psoriasis	6.34e-05	0.000365	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HCAR2—psoriasis	6.27e-05	0.000361	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TAGAP—psoriasis	6.27e-05	0.00036	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Betamethasone—psoriasis	6.23e-05	0.00926	CbGdCrCtD
Minocycline—IL1B—Budesonide—Dexamethasone—psoriasis	6.23e-05	0.00926	CbGdCrCtD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL6—psoriasis	6.2e-05	0.000356	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—JUN—psoriasis	6.19e-05	0.000355	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	6.16e-05	0.000354	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—NFKB1—psoriasis	6.11e-05	0.000351	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Triamcinolone—psoriasis	6.09e-05	0.00904	CbGdCrCtD
Minocycline—CASP3—Signaling by NGF—NFKB1—psoriasis	6.08e-05	0.00035	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	6.03e-05	0.000347	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-C—psoriasis	6.01e-05	0.000346	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.96e-05	0.000342	CbGpPWpGaD
Minocycline—IL1B—Immune System—TNFAIP3—psoriasis	5.94e-05	0.000341	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD8A—psoriasis	5.92e-05	0.00034	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TP53—psoriasis	5.88e-05	0.000338	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CD4—psoriasis	5.83e-05	0.000335	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TP53—psoriasis	5.78e-05	0.000332	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisone—psoriasis	5.78e-05	0.00858	CbGdCrCtD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.76e-05	0.000331	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	5.76e-05	0.000331	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-B—psoriasis	5.69e-05	0.000327	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	5.64e-05	0.000324	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisolone—psoriasis	5.64e-05	0.00838	CbGdCrCtD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL6—psoriasis	5.63e-05	0.000323	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL6—psoriasis	5.61e-05	0.000323	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—NFKB1—psoriasis	5.6e-05	0.000322	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Clobetasol propionate—psoriasis	5.57e-05	0.00828	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Clobetasol propionate—psoriasis	5.57e-05	0.00828	CbGdCrCtD
Minocycline—CYCS—Cellular responses to stress—TP53—psoriasis	5.51e-05	0.000317	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—STAT3—psoriasis	5.47e-05	0.000314	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TAGAP—psoriasis	5.44e-05	0.000313	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL20—psoriasis	5.41e-05	0.000311	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL6—psoriasis	5.38e-05	0.000309	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—JUN—psoriasis	5.28e-05	0.000304	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-A—psoriasis	5.27e-05	0.000303	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.26e-05	0.000302	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—JUN—psoriasis	5.22e-05	0.0003	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.06e-05	0.000291	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—IL6—psoriasis	5.05e-05	0.00029	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL6—psoriasis	5.05e-05	0.00029	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	5.04e-05	0.000289	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—STAT3—psoriasis	5.03e-05	0.000289	CbGpPWpGaD
Minocycline—CASP1—Immune System—CRP—psoriasis	5.03e-05	0.000289	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—NFKB1—psoriasis	5.03e-05	0.000289	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-E—psoriasis	4.99e-05	0.000287	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—TYK2—psoriasis	4.91e-05	0.000282	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-DRB1—psoriasis	4.82e-05	0.000277	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-05	0.000276	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—IL6—psoriasis	4.77e-05	0.000274	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—IL6—psoriasis	4.67e-05	0.000268	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—psoriasis	4.63e-05	0.000266	CbGpPWpGaD
Minocycline—CASP1—Immune System—ICAM1—psoriasis	4.62e-05	0.000266	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—LEP—psoriasis	4.59e-05	0.000264	CbGpPWpGaD
Minocycline—CASP1—Immune System—NFKBIA—psoriasis	4.59e-05	0.000264	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.51e-05	0.000259	CbGpPWpGaD
Minocycline—VEGFA—Betamethasone—Beclomethasone—psoriasis	4.46e-05	0.00663	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Fluocinonide—psoriasis	4.46e-05	0.00663	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Beclomethasone—psoriasis	4.46e-05	0.00663	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Fluocinonide—psoriasis	4.46e-05	0.00663	CbGdCrCtD
Minocycline—VEGFA—Cellular responses to stress—CXCL8—psoriasis	4.37e-05	0.000251	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Fluocinolone Acetonide—psoriasis	4.34e-05	0.00645	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Fluocinolone Acetonide—psoriasis	4.34e-05	0.00645	CbGdCrCtD
Minocycline—VEGFA—Axon guidance—TYK2—psoriasis	4.26e-05	0.000245	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CARM1—psoriasis	4.2e-05	0.000241	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CAT—psoriasis	4.19e-05	0.000241	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—TP53—psoriasis	4.19e-05	0.000241	CbGpPWpGaD
Minocycline—IL1B—Immune System—SOCS1—psoriasis	4.17e-05	0.00024	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Hydrocortisone—psoriasis	4.1e-05	0.0061	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Hydrocortisone—psoriasis	4.1e-05	0.0061	CbGdCrCtD
Minocycline—VEGFA—Cellular responses to stress—JUN—psoriasis	4.06e-05	0.000233	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—PPARG—psoriasis	4e-05	0.00023	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—LEP—psoriasis	3.98e-05	0.000229	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.94e-05	0.000226	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.93e-05	0.000226	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—NFKB1—psoriasis	3.91e-05	0.000225	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—IL6—psoriasis	3.82e-05	0.000219	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Betamethasone—psoriasis	3.81e-05	0.00566	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Dexamethasone—psoriasis	3.81e-05	0.00566	CbGdCrCtD
Minocycline—CASP1—Immune System—TYK2—psoriasis	3.76e-05	0.000216	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL20—psoriasis	3.75e-05	0.000216	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL6—psoriasis	3.74e-05	0.000215	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Triamcinolone—psoriasis	3.72e-05	0.00553	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Triamcinolone—psoriasis	3.72e-05	0.00553	CbGdCrCtD
Minocycline—IL1B—Immune System—CD8A—psoriasis	3.7e-05	0.000212	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS2—psoriasis	3.64e-05	0.000209	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-B—psoriasis	3.56e-05	0.000204	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Prednisone—psoriasis	3.53e-05	0.00525	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Prednisone—psoriasis	3.53e-05	0.00525	CbGdCrCtD
Minocycline—CASP1—Immune System—IFNG—psoriasis	3.52e-05	0.000202	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL6—psoriasis	3.52e-05	0.000202	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—STAT3—psoriasis	3.51e-05	0.000202	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TYK2—psoriasis	3.5e-05	0.000201	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.47e-05	0.0002	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—VEGFA—psoriasis	3.47e-05	0.000199	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—PPARG—psoriasis	3.47e-05	0.000199	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Prednisolone—psoriasis	3.45e-05	0.00513	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Prednisolone—psoriasis	3.45e-05	0.00513	CbGdCrCtD
Minocycline—CASP1—Immune System—CD4—psoriasis	3.4e-05	0.000195	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-A—psoriasis	3.3e-05	0.000189	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL20—psoriasis	3.26e-05	0.000187	CbGpPWpGaD
Minocycline—CYCS—Metabolism—APOE—psoriasis	3.26e-05	0.000187	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IL6—psoriasis	3.15e-05	0.000181	CbGpPWpGaD
Minocycline—IL1B—Immune System—CRP—psoriasis	3.14e-05	0.000181	CbGpPWpGaD
Minocycline—CASP1—Immune System—JUN—psoriasis	3.04e-05	0.000175	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TYK2—psoriasis	3.04e-05	0.000175	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DRB1—psoriasis	3.01e-05	0.000173	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SOCS1—psoriasis	2.98e-05	0.000171	CbGpPWpGaD
Minocycline—CASP1—Immune System—NFKB1—psoriasis	2.93e-05	0.000168	CbGpPWpGaD
Minocycline—IL1B—Immune System—ICAM1—psoriasis	2.89e-05	0.000166	CbGpPWpGaD
Minocycline—IL1B—Immune System—NFKBIA—psoriasis	2.87e-05	0.000165	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PPARG—psoriasis	2.84e-05	0.000163	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—NFKB1—psoriasis	2.73e-05	0.000157	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—TP53—psoriasis	2.68e-05	0.000154	CbGpPWpGaD
Minocycline—CASP1—Immune System—STAT3—psoriasis	2.63e-05	0.000151	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CAT—psoriasis	2.58e-05	0.000148	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—VEGFA—psoriasis	2.48e-05	0.000142	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL6—psoriasis	2.45e-05	0.000141	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—STAT3—psoriasis	2.45e-05	0.000141	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6—psoriasis	2.4e-05	0.000138	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—NFKB1—psoriasis	2.37e-05	0.000136	CbGpPWpGaD
Minocycline—IL1B—Immune System—TYK2—psoriasis	2.35e-05	0.000135	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFNG—psoriasis	2.2e-05	0.000126	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—LEP—psoriasis	2.2e-05	0.000126	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—APOE—psoriasis	2.2e-05	0.000126	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Hydrocortisone—psoriasis	2.19e-05	0.00326	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Hydrocortisone—psoriasis	2.19e-05	0.00326	CbGdCrCtD
Minocycline—VEGFA—Developmental Biology—STAT3—psoriasis	2.13e-05	0.000122	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD4—psoriasis	2.12e-05	0.000122	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—psoriasis	2.12e-05	0.000122	CbGpPWpGaD
Minocycline—CYCS—Levonorgestrel—Hydrocortisone—psoriasis	2.09e-05	0.00311	CbGdCrCtD
Minocycline—VEGFA—Axon guidance—IL6—psoriasis	2.08e-05	0.00012	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SOCS1—psoriasis	2.07e-05	0.000119	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NFKBIA—psoriasis	2.05e-05	0.000118	CbGpPWpGaD
Minocycline—VEGFA—Betamethasone—Dexamethasone—psoriasis	2.03e-05	0.00302	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Betamethasone—psoriasis	2.03e-05	0.00302	CbGdCrCtD
Minocycline—ALOX5—Metabolism—APOE—psoriasis	2.01e-05	0.000115	CbGpPWpGaD
Minocycline—VEGFA—Betamethasone—Triamcinolone—psoriasis	1.99e-05	0.00295	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Triamcinolone—psoriasis	1.99e-05	0.00295	CbGdCrCtD
Minocycline—IL1B—Immune System—JUN—psoriasis	1.9e-05	0.000109	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Prednisone—psoriasis	1.89e-05	0.0028	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisone—psoriasis	1.89e-05	0.0028	CbGdCrCtD
Minocycline—VEGFA—Developmental Biology—TNF—psoriasis	1.84e-05	0.000106	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Prednisolone—psoriasis	1.84e-05	0.00274	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisolone—psoriasis	1.84e-05	0.00274	CbGdCrCtD
Minocycline—CASP1—Immune System—IL6—psoriasis	1.84e-05	0.000106	CbGpPWpGaD
Minocycline—IL1B—Immune System—NFKB1—psoriasis	1.83e-05	0.000105	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SOCS1—psoriasis	1.79e-05	0.000103	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PPARG—psoriasis	1.75e-05	0.0001	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—IL6—psoriasis	1.71e-05	9.84e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TYK2—psoriasis	1.68e-05	9.64e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—STAT3—psoriasis	1.64e-05	9.45e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TP53—psoriasis	1.59e-05	9.15e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—LEP—psoriasis	1.53e-05	8.77e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—APOE—psoriasis	1.53e-05	8.77e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6—psoriasis	1.49e-05	8.54e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL8—psoriasis	1.46e-05	8.39e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NFKBIA—psoriasis	1.42e-05	8.17e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—JUN—psoriasis	1.36e-05	7.8e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—APOE—psoriasis	1.32e-05	7.61e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—LEP—psoriasis	1.32e-05	7.61e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NFKB1—psoriasis	1.31e-05	7.51e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NFKBIA—psoriasis	1.23e-05	7.09e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—VEGFA—psoriasis	1.19e-05	6.82e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—STAT3—psoriasis	1.17e-05	6.75e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TYK2—psoriasis	1.16e-05	6.69e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6—psoriasis	1.15e-05	6.6e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL8—psoriasis	1.01e-05	5.83e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TYK2—psoriasis	1.01e-05	5.81e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—JUN—psoriasis	9.43e-06	5.42e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NFKB1—psoriasis	9.07e-06	5.21e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TP53—psoriasis	8.96e-06	5.15e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL8—psoriasis	8.8e-06	5.06e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—VEGFA—psoriasis	8.23e-06	4.73e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6—psoriasis	8.2e-06	4.71e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—JUN—psoriasis	8.18e-06	4.7e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—STAT3—psoriasis	8.15e-06	4.68e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NFKB1—psoriasis	7.88e-06	4.53e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—STAT3—psoriasis	7.08e-06	4.07e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TP53—psoriasis	6.22e-06	3.57e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6—psoriasis	5.69e-06	3.27e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TP53—psoriasis	5.4e-06	3.1e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6—psoriasis	4.94e-06	2.84e-05	CbGpPWpGaD
